ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects

Erica Brivio, C. Michel Zwaan

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

20 Citaten (Scopus)

Samenvatting

There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology for specific entities such as ALK-driven inflammatory myofibroblastic tumor (IMT). IMT treatment can be challenging due to localization of the tumor and in rare cases of metastasis. When standard surgical treatment is not feasible, ALK inhibitors may play an important role, as recently reported for the first-generation ALK inhibitors (crizotinib). However, data on the second-generation ALK inhibitors are limited. We report two emblematic cases of IMT in pediatric patients, treated with the second-generation ALK inhibitor ceritinib in the context of a clinical trial (NCT01742286).

Originele taal-2Engels
Artikelnummere27645
TijdschriftPediatric Blood and Cancer
Volume66
Nummer van het tijdschrift5
DOI's
StatusGepubliceerd - mei 2019

Vingerafdruk

Duik in de onderzoeksthema's van 'ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects'. Samen vormen ze een unieke vingerafdruk.

Citeer dit